Stay updated with breaking news from Conditional Marketing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...
TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...
Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...
SAN DIEGO and ZUG, Switzerland, July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced the European Medicine Agency's Committee for...
CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2023, as well as key clinical and corporate developments. Clinical and Corporate Developments include: In... | June 14, 2023